ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
4.585
-0.235 (-4.88%)
At close: Apr 28, 2026, 4:00 PM EDT
4.670
+0.085 (1.85%)
After-hours: Apr 28, 2026, 6:05 PM EDT
ENDRA Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
5.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 514.03M |
| MDxHealth | 107.88M |
| Biodesix | 88.50M |
| Exagen | 66.58M |
| XWELL | 29.21M |
| Precipio | 24.05M |
| bioAffinity Technologies | 6.16M |
| iSpecimen | 1.93M |
NDRA News
- 4 weeks ago - ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 4 weeks ago - ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value - Business Wire
- 2 months ago - ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care - Business Wire
- 5 months ago - ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use - Business Wire
- 5 months ago - ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker - Business Wire
- 5 months ago - ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results - Business Wire
- 5 months ago - ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA - Business Wire
- 6 months ago - ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings - Business Wire